ACAD vs ERAS
ACADIA Pharmaceuticals Inc. vs Erasca, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
| Metric | ACAD | ERAS |
|---|
| AI Score |
69
|
62
|
| Price |
$29.41
|
$17.67
|
| P/E Ratio |
13.07×
|
-19.27×
|
| ROE |
31.9%
|
-38.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
0.0%
|
| Debt / Equity |
0.06×
|
0.12×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
48.1
|
| Beta |
0.845
|
0.665
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus ERAS.
ACAD leads by 7 points.
ACAD scores 69/100 (Buy) versus ERAS at 62/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
ERAS Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -77.0% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.7% signals elevated volatility — Risk